Stay updated on Fremanezumab Subq for Migraine Preven Clinical Trial
Sign up to get notified when there's something new on the Fremanezumab Subq for Migraine Preven Clinical Trial page.

Latest updates to the Fremanezumab Subq for Migraine Preven Clinical Trial page
- Check6 days agoChange DetectedThe ClinicalTrials.gov page now displays the completed fremanezumab migraine study record, with detailed trial information, results measures, participating locations, and downloadable study documents, instead of an access-denied error.SummaryDifference100%

- Check13 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2; the study page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedAn NIH-wide notice about website terminology changes appears above the page, which continues to show a 403 error. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check34 days agoChange DetectedThe site footer’s revision label changed from v3.7.0 to v3.7.1; the study page still displays a 403 Forbidden message.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page no longer lists the Study Documents and related metadata such as the Statistical Analysis Plan and Study Protocol, along with associated provider and publications details. This reduces access to supplementary materials for the NCT02638103 HALO study while keeping the main study overview intact.SummaryDifference18%

- Check62 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0 on the page, signaling a newer version of the ClinicalTrials.gov page. This appears to reflect internal updates or maintenance rather than a substantive change to study details or publicly visible content.SummaryDifference0.0%

Stay in the know with updates to Fremanezumab Subq for Migraine Preven Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fremanezumab Subq for Migraine Preven Clinical Trial page.